{"ok":true,"data":{"subject":{"kind":"trial","nctId":"NCT02711137","title":"Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies","sponsor":"Incyte Corporation","phases":["PHASE1","PHASE2"],"status":"TERMINATED","indication":null,"disease":"Solid Pseudopapillary Neoplasm of the Pancreas"},"rows":[{"n":1,"question":"Is the biology right?","flags":[{"id":"somatic_driver","label":"Somatic driver evidence","value":"no","detail":"None of PARP1, PARP3, PARP2, CYP17A1, AR, SRD5A1, JAK1, JAK2, JAK3 has somatic-mutation evidence in Solid Pseudopapillary Neoplasm of the Pancreas","rule":"Open Targets has somatic-mutation evidence for the target in this cancer","source":{"label":"Open Targets: PARP1 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000143799/EFO_1000542","date":"2026-11-11T21:01:47.390Z"},"context":[]},{"id":"human_genetic","label":"Human genetic evidence","value":"no","detail":"No germline or somatic evidence for PARP1, PARP3, PARP2, CYP17A1, AR, SRD5A1, JAK1, JAK2, JAK3 in Solid Pseudopapillary Neoplasm of the Pancreas","rule":"Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence","source":{"label":"Open Targets: PARP1 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000143799/EFO_1000542","date":"2026-11-11T21:01:47.390Z"},"context":[]},{"id":"pediatric_target","label":"Pediatric target","value":"yes","detail":"JAK1, JAK2, JAK3 on the FDA list","rule":"Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study","source":{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"},"context":[]},{"id":"haematologic","label":"Haematologic cancer","value":"no","detail":"Solid tumour","rule":"From the indication, or the registry conditions when no indication matches","source":{"label":"ClinicalTrials.gov NCT02711137","url":"https://clinicaltrials.gov/study/NCT02711137","date":"2026-11-11T21:01:47.390Z"},"context":[{"figure":"Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid","dataset":"BIO / Informa / QLS 2021","years":"2011–2020","caveat":"Population-level, not a prediction."}]}],"facts":[{"label":"Background therapy","text":"Azacitidine: standard agents, not counted in these flags."},{"label":"PARP1 (via Rucaparib)","text":"Open Targets has no association between PARP1 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: PARP1 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000143799/EFO_1000542","date":"2026-11-11T21:01:47.390Z"}},{"label":"PARP3 (via Rucaparib)","text":"Open Targets has no association between PARP3 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: PARP3 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000041880/EFO_1000542","date":"2026-11-11T21:01:47.390Z"}},{"label":"PARP2 (via Rucaparib)","text":"Open Targets has no association between PARP2 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: PARP2 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000129484/EFO_1000542","date":"2026-11-11T21:01:47.390Z"}},{"label":"CYP17A1 (via Abiraterone)","text":"Open Targets has no association between CYP17A1 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: CYP17A1 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000148795/EFO_1000542","date":"2026-11-11T21:01:47.390Z"}},{"label":"AR (via Abiraterone)","text":"Evidence types in Solid Pseudopapillary Neoplasm of the Pancreas: literature; literature listed separately from human genetics. Datasources: europepmc.","source":{"label":"Open Targets: AR in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000169083/EFO_1000542","date":"2026-11-11T21:01:47.390Z"}},{"label":"SRD5A1 (via Abiraterone)","text":"Open Targets has no association between SRD5A1 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: SRD5A1 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000145545/EFO_1000542","date":"2026-11-11T21:01:47.390Z"}},{"label":"JAK1 (via Ruxolitinib)","text":"Open Targets has no association between JAK1 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: JAK1 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000162434/EFO_1000542","date":"2026-11-11T21:01:47.390Z"}},{"label":"JAK2 (via Ruxolitinib)","text":"Open Targets has no association between JAK2 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: JAK2 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000096968/EFO_1000542","date":"2026-11-11T21:01:47.390Z"}},{"label":"JAK3 (via Ruxolitinib)","text":"Open Targets has no association between JAK3 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: JAK3 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000105639/EFO_1000542","date":"2026-11-11T21:01:47.390Z"}}],"pending":[{"what":"Normal-tissue expression in vital organs","source":"Human Protein Atlas (ticket 36)"},{"what":"Pan-essential in cell lines","source":"DepMap (ticket 36)"},{"what":"Approved drug on this target","source":"Drugs@FDA (ticket 30)"}]},{"n":2,"question":"Can the result be trusted?","flags":[{"id":"randomised","label":"Randomised","value":"no","detail":"Non-randomised","rule":"Registry allocation field","source":{"label":"ClinicalTrials.gov NCT02711137","url":"https://clinicaltrials.gov/study/NCT02711137","date":"2026-11-11T21:01:47.390Z"},"context":[]},{"id":"small_denominator","label":"Small denominator","value":"no","detail":"137 enrolled; each patient moves a rate by 100 ÷ 137 = 0.7 points","rule":"Enrolment under 30; the arithmetic is shown, not a benchmark","source":{"label":"ClinicalTrials.gov NCT02711137","url":"https://clinicaltrials.gov/study/NCT02711137","date":"2026-11-11T21:01:47.390Z"},"context":[]},{"id":"primary_os","label":"Primary endpoint is overall survival","value":"no","detail":"Number of Participants With Treatment Emergent Adverse Events (TEAE's).","rule":"A registered primary outcome measure names overall survival","source":{"label":"ClinicalTrials.gov NCT02711137","url":"https://clinicaltrials.gov/study/NCT02711137","date":"2026-11-11T21:01:47.390Z"},"context":[{"figure":"Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3","dataset":"Otsuka 2021, 400 phase 3 oncology trials","years":"to 2020","caveat":"Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival."},{"figure":"52% of surrogate-to-OS correlations are low","dataset":"Prasad 2015","years":"published to 2014","caveat":"Shown with the figure above."}]},{"id":"results_overdue","label":"Results overdue","value":"no","detail":"Results posted 2022-04-28","rule":"Primary completion (actual) more than 12 months ago and no results posted to the registry","source":{"label":"ClinicalTrials.gov NCT02711137","url":"https://clinicaltrials.gov/study/NCT02711137?tab=results","date":"2026-11-11T21:01:47.390Z"},"context":[]}],"facts":[],"pending":[{"what":"Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff","source":"Readout extraction (ticket 32)"},{"what":"Primary endpoint changed between registry versions","source":"Registry versions in the store (ticket 32)"}]},{"n":3,"question":"What must it beat?","flags":[],"facts":[],"pending":[{"what":"Control-arm result and approved therapies for the same segment, with label links","source":"Drugs@FDA, FDA labels and readouts (tickets 30, 32)"}]},{"n":4,"question":"Too crowded, or too late?","flags":[],"facts":[{"label":"Stopped on this target","text":"164 terminated, withdrawn or suspended trials of drugs against PARP1; 9 give no reason. Reasons are quoted as the registry gives them on the target page.","source":{"label":"PARP1: what already stopped","url":"/target/ENSG00000143799#stopped","date":"2026-11-11T21:01:47.447Z"}}],"pending":[{"what":"Programs on the target by phase and months behind the leader","source":"Programs and Drugs@FDA (ticket 33)"}]},{"n":5,"question":"Can it be approved, and stay approved?","flags":[{"id":"single_country","label":"Single-country","value":"no","detail":"18 sites in 3 countries; 16 in the United States (89%)","rule":"All listed sites are in one country; the share of US sites is shown","source":{"label":"ClinicalTrials.gov NCT02711137","url":"https://clinicaltrials.gov/study/NCT02711137?tab=locations","date":"2026-11-11T21:01:47.390Z"},"context":[]},{"id":"eu_pip","label":"EU paediatric investigation plan","value":"yes","detail":"EMEA-002618-PIP02-20-M01 (ruxolitinib (phosphate), Treatment of vitiligo): PM: decision on the application for modification of an agreed PIP, 12 Apr 2024; EMEA-002618-PIP04-23 (ruxolitinib (phosphate), Treatment of prurigo nodularis): W: decision granting a waiver in all age groups for all conditions or indications, 31 Jan 2024; EMEA-000901-PIP04-17-M02 (ruxolitinib (phosphate), Treatment of chronic Graft versus Host Disease (cGvHD)): PM: decision on the application for modification of an agreed PIP, 3 Dec 2021; compliance positive 13 Oct 2023; EMEA-000901-PIP03-16-M02 (ruxolitinib (phosphate), Treatment of acute graft-versus-host disease (aGvHD)): PM: decision on the application for modification of an agreed PIP, 9 Apr 2021; compliance positive 13 Oct 2023; +2 more","rule":"An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-paediatric_investigation_plans-output-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_orphan","label":"EU orphan designation","value":"yes","detail":"EU/3/12/1049 withdrawn 10 Oct 2012: Treatment of ovarian cancer; EU/3/14/1244 withdrawn 19 Feb 2014: Treatment of polycythaemia vera","rule":"An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-orphan_designations-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_authorised","label":"Authorised in the EU","value":"yes","detail":"Ruxolitinib Zentiva: opinion; Rubraca: authorised since 23 May 2018; Akeega: authorised since 19 Apr 2023; Opzelura: authorised since 19 Apr 2023; +5 more","rule":"An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"fda_orphan","label":"FDA orphan designation","value":"not published","detail":"FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link","rule":"Would be: an FDA orphan designation names the drug","source":{"label":"FDA orphan designations search","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/","date":""},"context":[]},{"id":"fda_ped_approval","label":"FDA pediatric oncology approval","value":"no","detail":"FDA's table lists no pediatric approval of INCB057643, Rucaparib, Abiraterone, Ruxolitinib","rule":"FDA's Pediatric Oncology Drug Approvals table names the drug","source":{"label":"FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03)","url":"https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals","date":"2026-11-11T21:01:47.463Z"},"context":[]},{"id":"studies_under_18","label":"Registered studies open to children","value":"yes","detail":"129 interventional studies of INCB057643, Rucaparib, Abiraterone, Ruxolitinib include patients under 18; 59 are recruiting, not yet recruiting or active","rule":"The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age","source":{"label":"ClinicalTrials.gov search","url":"https://clinicaltrials.gov/search?intr=%22INCB057643%22+OR+%22Rucaparib%22+OR+%22Abiraterone%22+OR+%22Ruxolitinib%22&aggFilters=ages%3Achild%2CstudyType%3Aint","date":"2026-11-11T21:01:47.472Z"},"context":[]}],"facts":[{"label":"Caveat","text":"Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality."},{"label":"Rare pediatric disease voucher","text":"FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news.","source":{"label":"FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs","url":"https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs","date":"2026-11-11"}}],"pending":[{"what":"Precedent approvals for target, modality and endpoint; accelerated-approval status","source":"Drugs@FDA and FDA accelerated-approval tables (ticket 30)"}]},{"n":6,"question":"Can the sponsor finish?","flags":[],"facts":[{"label":"Sponsor","text":"Incyte Corporation (industry)","source":{"label":"ClinicalTrials.gov NCT02711137","url":"https://clinicaltrials.gov/study/NCT02711137","date":"2026-11-11T21:01:47.390Z"}},{"label":"study director","text":"Fred Zheng, MD, PhD, Incyte Corporation","source":{"label":"Person page","url":"/person/Fred%20Zheng%2C%20MD%2C%20PhD","date":"2026-11-11T21:01:47.390Z"}}],"pending":[{"what":"Filed cash, quarterly spend and the runway arithmetic","source":"SEC XBRL company facts (ticket 37)"},{"what":"Sponsor's completed vs stopped oncology trials and results-reporting record","source":"Registry, by company (ticket 37)"}]}],"limits":"Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.","sources":[{"label":"ClinicalTrials.gov NCT02711137","url":"https://clinicaltrials.gov/study/NCT02711137","date":"2026-11-11T21:01:47.390Z"},{"label":"Open Targets Platform","url":"https://platform.opentargets.org","date":"2026-11-11T21:01:47.390Z"},{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"}]},"source":"ClinicalTrials.gov + Open Targets","fetchedAt":"2026-11-11T21:01:47.388Z"}